BACKGROUND & AIMS: The combination of erlotinib with sorafenib is currently being
investigated in a phase III RCT. We studied the effect of erlotinib and sorafenib on HCC in a …

Sorafenib targets the Raf/mitogen-activated protein kinase, VEGF, and platelet-derived
growth factor pathways and prolongs survival patients in advanced hepatocellular …

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a particularly vascularized solid
tumor where the Raf/MEK/ERK pathway is activated; suggesting that inhibition of this …

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is one of the most common cancer-
related causes of death worldwide. In light of the very poor 5-year-survival new therapeutic …

Surgical resection is the first‐line treatment for hepatocellular carcinoma (HCC) patients with
well‐preserved liver function. Nevertheless, the rate of postoperative recurrence at 5 years is …

Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest malignancy.
Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a …

BACKGROUND & AIMS: Sorafenib is the standard of care for the treatment of advanced
hepatocellular carcinoma (HCC). However, primary and acquired resistance is observed in …

Sorafenib, a multikinase inhibitor with antiangiogenic activity, is an approved therapy for
hepatocellular carcinoma (HCC). It is unclear whether the proinflammatory and …

Background Sorafenib is the only systemic agent to show statistically significant overall
survival (OS) benefits in advanced HCC. Erlotinib is a direct and reversible EGFR tyrosine …

Background: Sorafenib has recently been shown to reduce tumour growth in
hepatoblastoma (HB) xenografts. The effect of a combined administration with cytostatic …